O'Shares富時美國優質紅利ETF OUSA 深 滬
等待開盤 08-15 09:30:00 美东时间
55.475
-0.143
-0.26%
華盛通- 最 高55.547
- 今 開55.51
- 成交量 1.47万股
- 最 低 55.3376
- 昨 收 55.6184
- 總市值 8.36亿
- 52周最高 55.6184
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 46.9109
- 委 比 0.00%
- 總股本 1507.50万
- 歷史最高 55.6184
- 量 比 0.90
- 振 幅 0.38%
- 歷史最低 13.9219
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The div...
08-02 04:01
Catalyst Bancorp, Inc. Announces 2025 Second Quarter Results
OPELOUSAS, La., July 24, 2025 /PRNewswire/ -- Catalyst Bancorp, Inc. (Nasdaq: "CLST") (the "Company"), the parent company for Catalyst Bank (the "Bank") (www.catalystbank.com), reported net ...
07-24 19:00
漲超121% Opendoor成最新迷因股 成交額超車Meta
TradingKey - 美東時間週一（21日），房地產科技公司OpenDoor盤一度飆漲121%，最終收漲42%。由於波動劇烈，盤中一度被暫停交易。該股已連續第六個交易日上漲，六日漲幅高達312%，本月以來上漲502%。
07-22 11:36
Amgen Announces Full Results From Part 1 Of Phase 2 Study Of MariTide; Presents Complete Results From Primary Analysis Of Phase 1 PK-LDI Study Evaluating Lower Starting Doses Of MariTide At ADA 85th Scientific Sessions
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 WeeksIn
06-24 02:33
ALPS O'Shares U.S. Quality Dividend ETF Shares declares $0.0784 dividend
ALPS O'Shares U.S. Quality Dividend ETF Shares (BATS:OUSA) declared $0.0784/share monthly dividend. Payable June 25; for shareholders of record June 20; ex-div June 20. See OUSA Dividend Scorecard, Yi...
06-24 02:25
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025....
06-06 04:01
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Wednesday, May 14, 20...
05-10 04:01
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the fi...
05-02 04:01
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif., April 11, 20...
04-11 21:00
